Amneal Pharmaceuticals (AMRX) Cash from Operations (2017 - 2026)

Amneal Pharmaceuticals' Cash from Operations history runs 10 years deep, the most recent figure standing at 26743000.0 for Q1 2026.

• On a quarterly basis, Cash from Operations fell 461.0% year-over-year to 26743000.0 in Q1 2026; TTM through Mar 2026 was 305841000.0, a 0.35% change from a year earlier, with the FY2025 full-year figure at 339992000.0, up 15.21% from the prior year.
• Cash from Operations eased to 26743000.0 in Q1 2026 per AMRX's latest filing, from 130315000.0 in the prior quarter.
• Across five years, Cash from Operations topped out at 141774000.0 in Q3 2024 and bottomed at 125521000.0 in Q2 2022.
• The 5-year median for Cash from Operations is 83819000.0 (2025), against an average of 59942647.06.
• Across the five-year window, Cash from Operations soared 683.13% in 2023 and sank 461.0% in 2026, its largest moves.
• Year by year, Cash from Operations stood at 23292000.0 in 2022, then surged by 683.13% to 135823000.0 in 2023, then dropped by 13.06% to 118078000.0 in 2024, then increased by 10.36% to 130315000.0 in 2025, then plunged by 120.52% to 26743000.0 in 2026.
• Per Business Quant, the three latest AMRX Cash from Operations figures stand at 26743000.0 (Q1 2026), 130315000.0 (Q4 2025), and 118450000.0 (Q3 2025).